// immunotherapies

About
Immunotherapies

eTheRNA’s goal is to commercialize mRNA-based immunotherapies as off-the-shelf products for the treatment of cancer and infectious diseases.

To fight cancer, eTheRNA adopts multiple strategies including : 

New, pioneering immunotherapies using proprietary TriMix mRNA technology to stimulate and educate dendritic cells to create a potent, durable T-cell-mediated immune response against tumors in specific cancer indications. Different routes of administration (intranodal and intravenous) and different sources of antigens (tumor-associated antigens, viral antigens and shared neoantigens) are being deployed in different combinations in multiple development programs.

An mRNA-based approach mimicking the action of oncolytic viruses to induce immunogenic death of tumor cells.

An innovative mRNA mix that renders the tumor more susceptible towards the anti-tumor T cell response.

The different approaches can be combined with each other and other classes of treatment interventions.

To fight infectious diseases, eTheRNA is adapting its proprietary

TriMix technology to a product that can be administered intranasally and lead to antigen-specific T-cell-mediated mucosal immunity. This new approach is being applied to vaccines to protect against upper respiratory tract viruses including CoV-19 (coronavirus).

eTheRNA Pipeline Overview

Project Code

Project Name

Indication

Stage

Mode

Administration

Commercial Route

Oncology

A001

IN naked mRNA vaccine for melanoma

Metastatic melanoma

Phase I / II

Immuno-stimulation

Loco-regional (intranodal)

Orphan disease / partner late

A002

LNP based E6E7 vaccine

HNSCC

Preclinical

Immuno-stimulation

Systemic (IV)

Partner at preclinical

A003

IT optimized TriMix

Undisclosed

Lead opt'n

Oncolysis

Loco-regional (IT)

Partner at Phase II

A004

Cell death induction

Undisclosed

Lead opt'n

Oncolysis

Loco-regional (IT)

Partner at Phase II

A005

Frameshifted NeoAgs

RCC

Discovery

Immuno-stimulation

Systemic (IV)

Partner at preclinical

Non-Oncology

A006

NoseVAx

Infectious Disease

Discovery

Immuno-stimulation

Loco-regional (intranasal)

co-develop / early partner

A007

Novel immunotherapy

Undisclosed

Discovery

-

To be determined

To be determined

Technology

Platform expansion

ID / autoimmune

Discovery

-

Systemic (IV)

Partner

Galileilaan 19, 2845 Niel, Belgium

Our Address

Our Mailbox

+32 3 369 17 40

Our Phone

© 2020 Etherna | Studio Hanswijk